Ares Management’s Coherus Oncology CHRS Stock Holding History

Ares Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13,928	Closed	-$180K	–	39
2022 Q1	$180K	Hold	13,928	–	–	0.01%	39
2021 Q4	$222K	Hold	13,928	–	–	0.01%	44
2021 Q3	$224K	Hold	13,928	–	–	0.01%	46
2021 Q2	$193K	Hold	13,928	–	–	0.01%	46
2021 Q1	$203K	Hold	13,928	–	–	0.01%	40
2020 Q4	$242K	Hold	13,928	–	–	0.01%	34
2020 Q3	$255K	Hold	13,928	–	–	0.02%	34
2020 Q2	$249K	Hold	13,928	–	–	0.01%	33
2020 Q1	$226K	Buy	13,928 +2,500	+22%	+$46.2K	0.03%	40
2019 Q4	$206K	Hold	11,428	–	–	0.02%	49
2019 Q3	$232K	Hold	11,428	–	–	0.02%	52
2019 Q2	$253K	Hold	11,428	–	–	0.02%	46
2019 Q1	$156K	Hold	11,428	–	–	0.01%	61
2018 Q4	$103K	Buy	+11,428	New	+$132K	0.01%	74

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ares Management's CHRS Position: Q2 2022 in Review

Ares Management sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 13,928 shares — an estimated $180K sold.

Ares Management first reported a position in CHRS in Q4 2018 and held it in 14 quarters. The position peaked at $255K in Q3 2020. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

Ares Management reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
Ares Management sold 13,928 Coherus Oncology shares in Q2 2022, an estimated $180K.
Ares Management first reported a position in Coherus Oncology in Q4 2018 and held it in 14 quarters.
Ares Management's Coherus Oncology position peaked at $255K in Q3 2020.
176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Ares Management's 13F filing for Q2 2022, filed 12 Aug 2022.